Literature DB >> 22709414

A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.

Dennis Christensen1, Malou Henriksen-Lacey, Arun T Kamath, Thomas Lindenstrøm, Karen S Korsholm, Jan P Christensen, Anne-Francoise Rochat, Paul-Henri Lambert, Peter Andersen, Claire-Anne Siegrist, Yvonne Perrie, Else Marie Agger.   

Abstract

Adjuvants are often composed of different constituents that can be divided into two groups based on their primary activity: the delivery system which carries and presents the vaccine antigen to antigen-presenting cells, and the immunostimulator that activates and modulates the ensuing immune response. Herein, we have investigated the importance of the delivery system and in particular its physical characteristics by comparing the delivery properties of two lipids which differ only in the degree of saturation of the acyl chains, rendering the liposomes either rigid (DDA, dimethyldioctadecylammonium) or highly fluid (DODA, dimethyldioleoylammonium) at physiological temperature. We show that these delivery systems are remarkably different in their ability to prime a Th1-directed immune response with the rigid DDA-based liposomes inducing a response more than 100 times higher compared to that obtained with the fluid DODA-based liposomes. Upon injection with a vaccine antigen, DDA-based liposomes form a vaccine depot that results in a continuous attraction of antigen-presenting cells that engulf a high amount of adjuvant and are subsequently efficiently activated as measured by an elevated expression of the co-stimulatory molecules CD40 and CD86. In contrast, the fluid DODA-based liposomes are more rapidly removed from the site of injection resulting in a lower up-regulation of co-stimulatory CD40 and CD86 molecules on adjuvant-positive antigen-presenting cells. Additionally, the vaccine antigen is readily dissociated from the DODA-based liposomes leading to a population of antigen-presenting cells that are antigen-positive but adjuvant-negative and consequently are not activated. These studies demonstrate the importance of studying in vivo characteristics of the vaccine components and furthermore show that physicochemical properties of the delivery system have a major impact on the vaccine-induced immune response.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709414     DOI: 10.1016/j.jconrel.2012.03.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  26 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.

Authors:  Christopher B Fox
Journal:  Hum Vaccin Immunother       Date:  2013-06-20       Impact factor: 3.452

4.  Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.

Authors:  Signe Tandrup Schmidt; Malene Aaby Neustrup; Stine Harloff-Helleberg; Karen Smith Korsholm; Thomas Rades; Peter Andersen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2017-05-17       Impact factor: 4.200

Review 5.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

Review 6.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

Review 7.  Cationic Nanoparticle-Based Cancer Vaccines.

Authors:  Jeroen Heuts; Wim Jiskoot; Ferry Ossendorp; Koen van der Maaden
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

8.  Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.

Authors:  Pamela T Wong; Pascale R Leroueil; Douglas M Smith; Susan Ciotti; Anna U Bielinska; Katarzyna W Janczak; Catherine H Mullen; Jeffrey V Groom; Erin M Taylor; Crystal Passmore; Paul E Makidon; Jessica J O'Konek; Andrzej Myc; Tarek Hamouda; James R Baker
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 9.  Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.

Authors:  Maarten K Nijen Twilhaar; Lucas Czentner; Cornelus F van Nostrum; Gert Storm; Joke M M den Haan
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

Review 10.  Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?

Authors:  Babak Jalilian; Stig Hill Christiansen; Halldór Bjarki Einarsson; Mehdi Rasoli Pirozyan; Eskild Petersen; Thomas Vorup-Jensen
Journal:  Mol Cell Ther       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.